降糖西药治疗非酒精性脂肪性肝病并发2型糖尿病的研究进展

Research progress in hypoglycemic agents for nonalcoholic fatty liver disease complicated with type 2 diabetes mellitus

非酒精性脂肪性肝病(NAFLD)和2型糖尿病(T2DM)在临床上都是常见病,常同时存在或互相影响疾病的发生发展,胰岛素抵抗(IR)可能是它们共同发病的关键机制。近年来,NAFLD的患病率逐年上升,已成为发病率第一的肝病。某些降糖药物除了能有效管理血糖,还能改善肝脏脂肪变性、气球样变、肝纤维化和炎症指标,可能是治疗NAFLD的潜在药物。现就二甲双胍、DPP-4抑制剂、GLP-1受体激动剂、SGLT-2抑制剂、PPAR激动剂在治疗NAFLD合并T2DM患者中的作用效果进行综述,以期为NAFLD后续的药物研究和临床治疗提供参考。

Nonalcoholic fatty liver disease(NAFLD)and type 2 diabetes mellitus(T2DM)are both common.They often coexist or affect the occurrence and development of other diseases at the same time.Insulin resistance may be the key common pathogenesis.In recent years,the incidence rate of NAFLD has increased year by year.Current studies have shown that some hypoglycemic drugs can not only effectively manage blood glucose,but also improve liver steatosis,ballooning,liver fibrosis and inflammation indicators,which may be potential drugs for NAFLD.This article reviewed the effects of metformin,DPP-4 inhibitors,GLP-1 receptor agonists,SGLT-2 inhibitors,and PPAR agonists on NAFLD patients with T2DM,providing ideas for the treatment of NAFLD and reference for subsequent drug research.